BASF wants a share of pharma omega-3 market

BASF wants a share of pharma omega-3 market

BASF wants a share of the $1.5bn global market for drug grade omega-3 and expects the plant it is building to start shipping product early next year. 

The German chemicals giant acquired Equateq – now called BASF Pharma Callanish – in May, describing the Scotland-based firm as the global leader in the production of concentrated omega-3 fatty acids and citing its EPA and DHA products as key drivers for the deal.

in-Pharmatechnologist.com spoke with BASF spokesman Ralf Fink at CPhI in Madrid, Spain Iast week to ask how the firm views the current market and how it intends to grow this new part of its business.

“First of all the market is growing nicely and there is enough space for all of us. Today we see two major players in the market and the dominant player is Pronova…they created the market by having a technology in place to supply firms like GSK.”

To this end – Fink continued – BASF chose CPhI to showcase its own omega-3 active pharmaceutical ingredient (API), which it will produce at the new plant it is building in Callanish on the Isle of Lewis in Scotland.

The technology they are using is simulated moving bed technology…which is a patent protected, unique, cost efficient and very flexible manufacturing technology,” Fink said, adding that the plant’s ability to produce a variety of different omega-3 grades is key to meeting customers’ demands.

He declined to specify how much omega-3 BASF will be able to produce at the new plant – other than that it will be a substantial amount – but did say that: “It is a world class manufacturing facility…that we plan to have up and running and supplying product to our customers very early next year.” 

Related News

Vitamin price drops but BASF nutrition sees 4% sales growth

Vitamin price drops but BASF nutrition sees 4% sales growth

BASF shake-up wont impact pharma

BASF shake-up wont impact pharma business; China expansion

BASF bids $823m for Pronova

BASF bids $823m for GSK omega-3 supplier Pronova Biopharma

Supplements are important in its Pronova bid too, says BASF

Equateq, Cognis and Pronova: “Each are complementary”, says BASF

BASF expands Scottish omega-3 venture by 1000%

BASF commits €22m as it expands Scottish omega-3 venture 1000%

BASF commits Eur22m to Lewis, Scotland omega-3 facility

BASF confident it can get omega-3 to pharma customers whatever the weather

BASF nutrition president on omega-3 & the phood “white space”

BASF nutrition president on high-end omega-3, Equateq and the phood “white space”

BASF extends ProNova offer; DSM confirms Fortitech buy

M&A: BASF extends ProNova offer after only 67% sell; DSM confirms Fortitech buy

BASF extends Pronova offer

BASF wont extend Pronova offer again

Amarin seeks US FDA OK for omega-3 supplier BASF

US approval for omega-3 suppliers BASF and Chemport key for Amarin in 2013

BASF ups offer for omega-3 API maker Pronova

BASF ups offer for omega-3 API maker Pronova

BASF wins over Pronova shareholders

BASF sees synergies between new acquisition Pronova and Equateq

Bioseutica sells high-end omega-3 division

Bioseutica sells high-end omega-3 division to German equity firm; major expansion planned

BASF talks excipients, raw materials and development plans at CPhI 2011

BASF talks excipients, raw materials and development plans at CPhI 2011

BASF EOA

BASF ups EOA prices again

BASF renames solubilisation and dermatology excipients

BASF renames solubilisation and dermatology excipients

BASF to build in India

BASF to build biocatalysis line in India

BASF to build formic acid plant in US

BASF to build formic acid plant in US

BASF chitosan seagarden pharma

BASF sells chitosan biz to firm with eye on pharma

BASF working on drug formulations that can be delivered via the skin

BASF opens dermatology lab to solve formulation challenges

BASF working on drug formulations that can be delivered via the skin

BASF focuses on topical formulations to solve skin delivery challenges

BASF selects Asia-Pacific excipients distributor

BASF selects Asia-Pacific excipients distributor

Related Products

See more related products